UCL/Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom; Technion, Institute of Technology, Bnai Zion Medical Center, Haifa, Israel.
Save Sight Institute, Sydney Medical School, Sydney, Australia.
Am J Ophthalmol. 2018 Jun;190:164-170. doi: 10.1016/j.ajo.2018.03.032. Epub 2018 Mar 29.
To describe the clinical features of patients with uveitis associated with latent tuberculosis (TB) and examine the effect of anti-TB treatment (ATT) on uveitis outcome.
Retrospective cohort study.
One hundred ninety-nine eyes of 129 patients diagnosed with uveitis associated with latent TB were evaluated for recurrence of disease following treatment. Eighty-nine of the patients (69%) received ATT and information was gathered retrospectively regarding clinical outcome, vision, and treatment. Outcome measures included best-corrected visual acuity (BCVA) and rate of disease recurrence.
This study included 89 patients (69%) who received ATT and 40 patients who did not. The uveitis was treated with local and systemic anti-inflammatory and immunosuppressive therapy in all patients. The mean change in BCVA following treatment was 4.5 ± 1.4 letters over the follow-up period, with no difference between eyes of patients receiving ATT and those who did not. Sixty-eight eyes (34.9%) had a recurrence of uveitis (0.64 ± 0.08 recurrences per year), with eyes of patients receiving ATT less likely to develop a recurrence compared to those not receiving ATT (29.5% vs 48.2%, odds ratio 0.47, 95% confidence interval 0.29-0.77, P = .003). Eyes treated with ATT recurred at an estimated median of 120 months, compared with 51 months in eyes with no treatment (P = .005).
Treatment with ATT halved the risk of uveitis recurrence and delayed the onset of the first recurrence in eyes with uveitis associated with latent TB.
描述与潜伏性结核(TB)相关的葡萄膜炎患者的临床特征,并研究抗结核治疗(ATT)对葡萄膜炎结局的影响。
回顾性队列研究。
评估了 129 例经诊断患有与潜伏性 TB 相关的葡萄膜炎的患者的 199 只眼,以评估治疗后疾病复发的情况。其中 89 例(69%)患者接受了 ATT,回顾性收集了关于临床结局、视力和治疗的信息。主要结局指标包括最佳矫正视力(BCVA)和疾病复发率。
本研究纳入了 89 例(69%)接受 ATT 的患者和 40 例未接受 ATT 的患者。所有患者均接受局部和全身抗炎和免疫抑制治疗。治疗后 BCVA 的平均变化为随访期内 4.5 ± 1.4 个字母,接受 ATT 的患者与未接受 ATT 的患者之间无差异。68 只眼(34.9%)发生葡萄膜炎复发(每年复发 0.64 ± 0.08 次),接受 ATT 的患者眼发生复发的可能性低于未接受 ATT 的患者眼(29.5%比 48.2%,比值比 0.47,95%置信区间 0.29-0.77,P =.003)。接受 ATT 治疗的眼复发的估计中位数为 120 个月,而未接受治疗的眼为 51 个月(P =.005)。
ATT 治疗可使与潜伏性 TB 相关的葡萄膜炎患者的葡萄膜炎复发风险降低一半,并延迟首次复发的发生时间。